The firm`s founder, Dipl. Natw. ETH, Dr.sc.nat. ETH, Gilles Reiss(-Hürlimann), *1968, spent more than 10 years working in chemical industry as a patent attorney, with an international perspective and with directly representing corporate client in all EPO proceedings (2000-2007 Lonza AG, Basel/CH, 2007-2011 Basell Polyolefin GmbH, Frankfurt/DE - pharmaceuticals/speciality chemicals and performance polymers, respectively) . He regularly worked on international supply and license contracts in industry as well as on patent enforcement & litigation/freedom to operate.
Mr. Reiss is both a qualified Swiss and European Patent Attorney (both professional titles protected under the law). Being a native of Frankfurt/Main, he graduated from the Swiss Institute of Technology (ETH) in 1993 in interdisciplinary natural sciences, ( Dipl. Natw. ETH: organic chemistry, polymer structure/(bio)physics, biomimetic synthesis/biochemistry ). Additional specialisation was on carbohydrate and peptide chemical synthesis. All coursework in organic chemistry was carried out as regular chemistry student assignment at the chemistry department of ETH (that time: Abtlg. IV); advanced coursework was done in the group of Prof. Eschenmoser at ETH, he himself having graduated as a Natural Scientist (Dipl. sc. Nat.) from ETH. The polymer part was drawn to purification and structure elucidation of polymers, with a focus on particular C13- and H-NMR techniques for polymer characterization, including the lecture and practice of multidimensional NMR methodologies, in particular for the analysis of biopolymers (lecture and exercises rendered by Prof. K. Wüthrich, Nobel Prize Winner 2002). Nowadays, a basically similiar study curriculum continues to exist, assigned to the lately formed joint department of chemistry and applied biosciences (as Bsc./Msc. `Nat. sc.`) .
After having further earned a Ph.D. degree from ETH in 1997, Dr. Reiss started his career in Intellectual Property: After a postgraduate, full-time course training in Swiss Contract and IP law at ETH Zurich, he started working in Swiss finechemical industry, full time. In parallel to this on-job duties, Dr. Reiss conducted a 2y distance study in English (Common) Law, notably English legal method, contract and tort law, at Nottingham Law School (Nottingham Trent University, UK) and earned his qualification in European Patent Law (including, the European bar exam as Europ. Patent Attorney). After having passed the European bar exam, he obtained the diploma certificate in European Patent Litigation from U. Strasbourg (epi/Ceipi joint 1-y professional course, 06/07) that is intended to qualify European Patent Attorneys for representing clients at the forthcoming EU Patent Court, as foreseen steadily in the EU draft agreement text.
Supplementarily, you may browse the profile of Dr. Reiss-Hürlimann on Linkedin.com.
Case law references
*=represented patentee, otherwise opponent
1. EPO, successful board of appeal cases (inter partes cases only, i.e. final instance court in opposition cases, deciding on nullity of granted EP patent, non-appealable)
Basell EP-1228101 *
BorealisEP-1333044 (Borealis offered to settle Jan. 11, prior to oral trial in Feb..)
2. EPO, opposition division (1st instance nullity cases at the EPO)
ChevronPhilips EP1749 060
Glaxo EP-504 363
LaJolla Cancer Research EP-751709
3. Drafting / prosecution (selection; note: where *, only prosecution)
EP-2239283 B (filed: Nov. 2009/ R.71.3 com. issued 2011)
BASELL POLYOLEFINE GmbH
Novel LDPE from high pressure tubular reactor, for medical use/blow-fill-seal sterile products such as infusion bags, allowing ofshortened sterilization treatment.
- opposition period not yet expired
WO 2009/103516 , Basell Polyolefine GmbH,
PE coating for steel pipes and other purposes, cable sheating, rotomoulding(Rotomoulding appliance continuted in WO 2011-/020622, -621, 620 ).
- granted EP Patent now opposed by Borealis (Aug. 2012)
| . || (WO 2011/000497) POLYETHYLENE MOULDING COMPOSITION || 06.01.2011 || || || BASELL POLYOLEFINE GMBH || |
| || A novel polyethylene composition is described. The composition is suitable for manufacturing especially stretched bands or tapes, also coined raffia in the art. || |
| || || |
| . || (WO 2010/063432) PROCESS FOR THE POLYMERIZATION OF ETHYLENE, AND ETHYLENE POLYMERS HAVING BROAD MOLECULAR WEIGHT DISTRIBUTION AND LONG- CHAIN BRANCHING || 10.06.2010 || || || BASELL POLYOLEFINE GMBH || || || |
| || New ethylene polymers having broad molecular weight distribution and long-chain branching, above all at high molecular weight fractions; the polymers have strain hardening equal or higher than 1.4 (at constant elongational rate of 0.5s-1, at 150°C), branching index g' equal or lower than 0.9 (at Mw of 2⋅10exp6 g/mol). The polymers are prepared by using a mixed catalyst system comprising a polymerization catalyst based on a late transition metal component having a tridentate ligand, and a Ziegler polymerization catalyst annealed at a temperature higher than 100°C, for a time of at least 10 minutes. || |
| 17. || (WO 2010/034520) IMPACT RESISTANT LLDPE COMPOSITION AND FILMS MADE THEREOF || 01.04.2010 || || || BASELL POLYOLEFINE GMBH || |
| || A novel PE material is devised showing excellent mechanical/optical properties and process ability, e.g. for film extrusion. The polyethylene of the invention is produced in one single e.g. gas phase reactor. || |
| || |
| 18. || (WO 2010/034508) IMPACT RESISTANT LLDPE COMPOSITION AND FILMS MADE THEREOF Dito, s. No. 17 above || 01.04.2010 || || || BASELL POLYOLEFINE GMBH || || |
| || (WO 2010/139419) POLYETHYLENE COMPOSITION AND FINISHED PRODUCTS MADE THEREOF || 09.12.2010 || || || BASELL POLYOLEFINE GMBH || |
| || Novel polyethylenes having defined molecular weight distribution and LCB structure are devised, for films or mouldings. |
(note: PRIORITY APPLICATIONS drafted & filed by G. Reiss; PCT was filed after leave from Lonza)
A novel process for the preparation of lamotrigine (3,5-Diamino-6-(2,3-dichlorphenyl)- 1,2,4-triazin), an active pharmaceutical ingredient, and its intermediates is devised, using sulfonic acid both as a solvent and acidifier.
Methodof synthesizing a compound of formula (I), wherein Rl, R2 are, independently,chloro or fluoro, and wherein R3 is H, alkyl, aralkyl or is an alkylether oralkylthioether comprising the steps of firstly reducing a diazeny compound offormula (II) non-catalytically or with a catalytic amount of an homogenousorganic, non-metal catalyst to the corresponding hydrazo compound of formula(III) and in a second step catalytically hydrogenating said hydrazo compound inwith a heterogeneous Ni-catalyst to the compound of formula (I).
Anew method of synthesizing GLP-1 peptide is devised.
Amethod for the solid phase peptide synthesis of thymosin alpha-1 is disclosed.The peptide or fragments thereof are synthesised on a polyethylene glycol (PEG)resin. The method provides high yields and pure products.
Anovel method for on-resin, disulfide-borne cyclization of peptides is devised.
Methodof peptide synthesis, comprising the steps of a. synthesizing a peptide linkedto a solid phase which peptide comprises at least one cysteine, homo- ornor-cysteine residue, which cysteine is protected in its side chain by aS-tert.butyl-sulphenyl group b. either coupling N-terminally a further aminoacid having a 3,3'-dithio-(1--carboxy-propyl)-propionyl-radical on its Nα ordeprotecting the Nα of the N-terminal amino acid and reacting the free Nα with3,3'-dithio-propionic acid imide to yield the correspondingNα-3,3'-dithio-(1-carboxy-propyl)--propionamide or deprotecting the Nα of theN-terminal amino acid and reacting the free Nα with a compound of formula IVR7-S-S-[CH2]2-COOH IV wherein R7 is ar...
A novel method for side chain cyclisation ofpeptides by means of lactamization is provided, as shown on the example ofbremelanotide (PT-41) derivatives . – Opposedby Novo Nordisk
Anovel method for amidation of C-terminal carboxyl groups of peptides isdevised, which methods avoids undesired epimerisation of the α-carbon of theC-terminal amino acid yielding diastereoisomeric variants of the amidatedpeptide.
WO(2004/076485) Lonza Biologics – Chromatography method for purifying therapeutic antibodies.
Inventors: Julian Bonnerjea & Anna Preneta – opposed by not less than 6 competitor companies at the European Office, after grant! –also cp.above the opposition brief drafted against chromatography patents of Genentech & Glaxo
WO 2009/103516 , PE coating for steel pipes(Rotomoulding Anwendung ist in WO 2011-/020622, -621, 620 weitergeführtworden)
WO 2010/025918 Trimodales Ziegler-PE(Hostalen) mit PB-1 for piping (priority application, PCT filed & handled by a colleague)
EP-1379676 (WO02/074737) – Process for the preparation of 2-Hydroxymethyl-Pyrrolidine-3,4-Diols
A process for thepreparation of 2-hydroxymethyl-pyrrolidine-3,4-diols of the formulae comprisingthe steps of a) biooxidation of N-protected aminotetraols of the formula b)deprotection of the corresponding N-protected 5-amino-5-deoxy-pentulose c)hydrogenation of the corresponding 5-amino-5-deoxy-pentulose .
4. Varia (e.g. appeal brief in US prosecution, body of argument adopted unamended by US colleague)
Instructed prosecution and provided draft appeal brief on material patentability/lack of primafacie obviousness for ex parte appeal of USSN 09/867552
PROCESS FOR THE PREPARATION OF N-(AMINO-4, 6-DIHALO- PYRIMIDINE)- FORMAMIDES (Saikali et al.) by phase transfer catalysis
including(at prosecution or appeal stage) an 1.131 affidavit signed by inventor, outlining and corroborating the technical merits in support of our non-obviousness argument.